产品
编 号：F511486
分子式：C18H32O16
分子式：C18H32O16
产品类型
规格
价格
是否有货
100mg
400
In-stock
结构图
CAS No: 9008-22-4
产品详情
生物活性：
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as?laminarinase?(EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.
体内研究：
Laminaran (intravenous injection; 12.5, 25, and 50 mg/kg; 21 days) and OVA (50 μg) combination significanly decreases the tumor masses when it compares with the PBS-, OVA-, and laminarin-treated mice.Animal Model:C57BL/6 mice injected?s.c. with B16-OVA cells
Dosage:12.5, 25, and 50 mg/kg; 21 days
Administration:Intravenous injection
Result:Prevented B16-OVA tumor growth by inducing Ag-specific immune responses.
体外研究：
Laminaran (100-800 μg/mL; 24 hours) is not cytotoxic against normal epidermal cells JB6 Cl41 and human melanoma cells SK-MEL-28, the percentage of inhibition of living cells number is less than 15 % at concentrations range up to 800 μg/mL after 24 h of treatment.Laminaran (200 μg/mL; 24-72 hours)does not cause any growth inhibition of SK-MEL-28 cells after 24 and 48 h of treatment, but decreases cells proliferation by 36 % after 72 h of treatment.Laminaran (25-50 μg/mL; 24 hours) at low concentration does not influence the phosphorylation of c-Raf (Ser259), ERK1/2 (Tyr202/Tyr204), and MEK1/2 (Ser 221) kinases as well as total expression level of investigated proteins. But decreases p-MEK, p-ERK1/2 at 50 μg/mL.
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as?laminarinase?(EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.
体内研究：
Laminaran (intravenous injection; 12.5, 25, and 50 mg/kg; 21 days) and OVA (50 μg) combination significanly decreases the tumor masses when it compares with the PBS-, OVA-, and laminarin-treated mice.Animal Model:C57BL/6 mice injected?s.c. with B16-OVA cells
Dosage:12.5, 25, and 50 mg/kg; 21 days
Administration:Intravenous injection
Result:Prevented B16-OVA tumor growth by inducing Ag-specific immune responses.
体外研究：
Laminaran (100-800 μg/mL; 24 hours) is not cytotoxic against normal epidermal cells JB6 Cl41 and human melanoma cells SK-MEL-28, the percentage of inhibition of living cells number is less than 15 % at concentrations range up to 800 μg/mL after 24 h of treatment.Laminaran (200 μg/mL; 24-72 hours)does not cause any growth inhibition of SK-MEL-28 cells after 24 and 48 h of treatment, but decreases cells proliferation by 36 % after 72 h of treatment.Laminaran (25-50 μg/mL; 24 hours) at low concentration does not influence the phosphorylation of c-Raf (Ser259), ERK1/2 (Tyr202/Tyr204), and MEK1/2 (Ser 221) kinases as well as total expression level of investigated proteins. But decreases p-MEK, p-ERK1/2 at 50 μg/mL.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备